Nordic Life Science
Staten Biotechnology and Novo Nordisk have announced that they have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia. Under the collaboration
If any city could lay claim to the title of Sweden’s intellectual capital, Umeå would be it. Located in northeastern Sweden and home to about 120 000 people - and
The two companies have announced that they have entered into an exclusive collaboration to develop the OnDosis’ technology for prescription medicines in all pain related indications. The agreement also entails
Elypta’s co-founder and Chief Scientific Officer, Francesco Gatto, has been named Pioneer of the Year at MIT Technology Review’s European Innovators Under 35 Summit in Paris. The co-founder of the Swedish liquid-biopsy startup Elypta
Earlier this week, extraordinary scientific discoveries were honored during the Nobel Prize Award Ceremony. Nordic Life Science has interviewed the Laureates for our upcoming Nobel Prize special issue. This year, three
AMRA Medical has received FDA clearance for AMRAÒ Profiler, now available for use in a clinical setting in the US. AMRAÒ Profiler is indicated for use as a magnetic resonance
Sponsored Content
Drug & Device development
All patients in the company’s phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial and no dose limiting toxicities (DLTs) were
Nordic Nanovector announces that updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin (177Lu-lilotomab-satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma (R/R iNHL) have been presented in
The company has presented a comprehensive analysis of monotherapy data from its BGBC003 clinical trial (NCT02488408) with selective AXL inhibitor bemcentinib in patients with relapsed/refractory Acute Myeloid Leukaemia (AML) or
The company is partnering with Beijing University Cancer Hospital and Konica Minolta in a clinical trial to assess the efficacy of scalp cooling for chemotherapy-induced hair loss in women with
LIDDS adds two major university clinics in Lithuania to its ongoing Phase IIb study, the National Cancer Institute in Vilnius and the University Clinic of Kaunas. The two clinics are
The company has announced new data from the CERTiFy (CERAMENT Treatment of Tibia Plateau Fracture defects) study comparing CERAMENT|BVF with autologous iliac bone graft (autograft). “Successfully completing the ground-breaking CERTiFy study, to demonstrate
Staten Biotechnology and Novo Nordisk have announced that they have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia. Under the collaboration
Latest news
All patients in the company’s phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial and no dose limiting toxicities (DLTs) were
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
All patients in the company’s phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial and no dose limiting toxicities (DLTs) were
Nordic Nanovector announces that updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin (177Lu-lilotomab-satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma (R/R iNHL) have been presented in
The company has presented a comprehensive analysis of monotherapy data from its BGBC003 clinical trial (NCT02488408) with selective AXL inhibitor bemcentinib in patients with relapsed/refractory Acute Myeloid Leukaemia (AML) or
The company is partnering with Beijing University Cancer Hospital and Konica Minolta in a clinical trial to assess the efficacy of scalp cooling for chemotherapy-induced hair loss in women with
LIDDS adds two major university clinics in Lithuania to its ongoing Phase IIb study, the National Cancer Institute in Vilnius and the University Clinic of Kaunas. The two clinics are
The company has announced new data from the CERTiFy (CERAMENT Treatment of Tibia Plateau Fracture defects) study comparing CERAMENT|BVF with autologous iliac bone graft (autograft). “Successfully completing the ground-breaking CERTiFy study, to demonstrate
A1M Pharma announces that the Swedish Medical Products Agency has granted permission to start a clinical Phase I study of ROSgard – a drug candidate developed to prevent Acute Kidney
The company announces that the dosing of patients in its first trial PP-CT01, studying the safety and tolerability of XEN-D0501 in patients with type 2 diabetes, was completed. XEN-D0501 is
Swedish ExpreS2ion Biotech Holding AB announces that The Jenner Institute of the University of Oxford have presented positive results from its Phase I/IIa clinical studies with their RH5.1 bloodstage malaria
The first patient has been dosed in a Phase 2 study evaluating the company’s cancer immunotherapy, BN-Brachyury, and radiation in patients with advanced chordoma. Chordoma is a rare cancer that
The company announces that the first patient has been dosed in the Archer-1 trial investigating Betalutin (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL). Rituximab is
The new trial evaluates the combination therapy of CV301 and durvalumab in metastatic colorectal and pancreatic cancers. The first patient has been dosed in a clinical study evaluating CV301, the
The company has announced that DAYBREAKi, the first phase III study for Lu AF35700, an investigational, novel, once-daily, oral antipsychotic drug candidate for the potential treatment of treatment-resistant schizophrenia (TRS), did
The company has announced results from its phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an investigational GLP-1 analogue taken
The company has presented results from its HARMONIZE Global Phase III trial, which investigated the safety and efficacy of Lokelma (sodium zirconium cyclosilicate) vs. placebo in patients with hyperkalaemia in Japan, Korea,
The latest research news from the Nordic region
Science Article
Elypta’s co-founder and Chief Scientific Officer, Francesco Gatto, has been named Pioneer of the Year at MIT Technology Review’s European Innovators Under 35 Summit in Paris. The co-founder of the Swedish liquid-biopsy startup Elypta
On December 7, Professor Reuss, from the University of Stuttgart, received the Novozymes Award for Excellence in Biochemical and Chemical Engineering 2018. “We are awarding Matthias Reuss for his ground-breaking contribution to
Highly Cited Researchers from Clarivate Analytics is an annual list recognizing leading researchers in the sciences and social sciences from around the world and this year, Jaakko Kaprio and Samuli
It is once again time to honor extraordinary scientific discoveries. And this year, three of the Prizes have important life science applications, including cancer immunotherapy, eye operations and the production of new
According to a Nordic study the use of a new class of drugs in the treatment of type 2 diabetes, so called SGLT2 inhibitors, are linked to a twofold increased
He Jiankui, a genome-editing researcher at the Southern University of Science and Technology of China in Shenzhen, claims to have impregnated a woman with embryos that had been edited to disable